| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-23484SS | |||
| Azide and BSA Free | NBP2-81015 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56709SS | |||
| Azide and BSA Free | NBP2-80613 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2682SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-54791SS | |||
| Azide and BSA Free | NBP2-80822 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56583SS | |||
| Azide and BSA Free | NBP2-80872 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-32932-0.02mg | |||
| Azide and BSA Free | NBP2-34713-0.2mg | |||
| Azide and BSA Free | NBP2-34713-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-488SS | |||
![Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0014.jpg "<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunocytochemistry-Immunofluorescence-NBP2-23484-img0009.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human cervical cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0006.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on U-87 cells with ZEB1 [2A8A6] Antibody NBP2-23484AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0012.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 expression was assayed in lung adenocarcinoma cells after transfectionwith miR-33b or miR-NC, anti-miR-33b or anti-miR-NC in H1299 and A549 cells. Image submitted by verified customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0013.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human recturm cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0004.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - Flow cytometric analysis of Hela cells using ZEB1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0007.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on with A549 cells with ZEB1 Antibody NBP2-23484PE and a a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0010.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on Jurkat with ZEB1 Antibody (2A8A6) NBP2-23484 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse F(ab)2 IgG (H+L) PE-conjugated Antibody (R&D Systems, F0102B)](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0011.jpg)
![Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Curcumin Analogs Induce Apoptosis in Cancerous Cells by Several Pathways. E6-1 cells were treated for 24 hours with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK and the studied compounds, lysed and subjected to Western blot analysis. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-01230-4) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0009.jpg "<b>Biological Strategies Validation. </b>Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Curcumin Analogs Induce Apoptosis in Cancerous Cells by Several Pathways. E6-1 cells were treated for 24 hours with or without the broad spectrum caspase inhibitor ZVAD(oMe)-FMK and the studied compounds, lysed and subjected to Western blot analysis. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-01230-4) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: Caspase-3 Antibody (31A893) [NB100-56709] - Tissue section of normal human breast using 5 ug/mL concentration of . Very strong diffused as well as granular immunopositivity of Caspase 3 was observed specifically in the cytoplasmic of ductal /acinar epithelial cells.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunohistochemistry-Paraffin-NB100-56709-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: Caspase-3 Antibody (31A893) [NB100-56709] - Left panel: Untreated Jurkat cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with at 10 ug/mL overnight at 4C and detected with an anti-Mouse IgG Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunocytochemistry-Immunofluorescence-NB100-56709-img0008.jpg)
![Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Analysis for human Caspase-3 using HL60 lysates with Caspase-3 Antibody (31A893) at 2 ug/mL dilution. NB100-56709 only detects a 32 kD Caspase-3 corresponding to pro-Caspase-3.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0005.jpg)
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: Caspase-3 Antibody (31A893) [NB100-56709] - Analysis of Caspase-3 in Jurkat cells. Cells were treated with 2 uM staurosporine for different time periods. Caspase-3 activation is detected in Western blots by the presence of Caspase-3 cleavage fragments. These antibodies detect both pro (full-length) and active (cleaved) Caspase-3, depending on the treatment time points. A basal level of endogenous active Caspase-3 may be see in untreated Jurkat cells.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Western-Blot-NB100-56709-img0006.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody (31A893) [NB100-56709] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue using 5 ug/mL of mouse monoclonal Caspase-3 Antibody (31A893) (NB100-56709, Novus Biologicals), for 1 hour at room temperature followed by anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-31A893-Immunohistochemistry-Paraffin-NB100-56709-img0007.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Lemongrass extract is dependent on the production of oxidative stress to induce apoptosis. (E) E6-1 cells treated for 3 hrs with LG with or without NAC, lysed, & subjected to SDS-PAGE. Cells then transferred to a PVDF membrane & probed for the specific proteins. Bands visualized with a chemiluminescence reagent. Statistical calculations performed using Two-Way ANOVA multiple comparison for (A) & One-Way ANOVA multiple comparison for (B–C). **p < 0.01 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-31020241535657.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Functioning FADD protein is required to induce apoptosis in cancer cells treated with lemongrass extract(A) U-937 & (B) DN FADD Jurkat cells were treated for 12 hours & 48 hours, respectively, with the specified treatments, lysed, & subjected to SDS-PAGE. Cells were then transferred to a PVDF membrane & probed for the specific proteins. Bands were visualized with a chemiluminescence reagent. (C) DN FADD Jurkat cells were treated for 48 hours with the specified doses & stained with Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (D) DN FADD Jurkat cells were treated with H2DCFDA following treatments with paraquat (PQ), LG, or WT for 3 hours. Results were obtained using the image-based cytometry with the Y-axis representative of percent of cells positive for DCF. Values are expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison for (C) & One-Way ANOVA multiple comparison for (D). ***p < 0.001 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-310202415525230.jpg)
![Western Blot: Caspase-3 Antibody (31A893) - BSA Free [NB100-56709] - Functioning FADD protein is required to induce apoptosis in cancer cells treated with lemongrass extract(A) U-937 & (B) DN FADD Jurkat cells were treated for 12 hours & 48 hours, respectively, with the specified treatments, lysed, & subjected to SDS-PAGE. Cells were then transferred to a PVDF membrane & probed for the specific proteins. Bands were visualized with a chemiluminescence reagent. (C) DN FADD Jurkat cells were treated for 48 hours with the specified doses & stained with Annexin V & PI. Results were obtained using image-based cytometry with the Y-axis representative of percent of cells positive for Annexin V (green), PI (red), Annexin V & PI (yellow), or negative for both Annexin V & PI (blue). Values are expressed as a mean ± SD from three independent experiments. (D) DN FADD Jurkat cells were treated with H2DCFDA following treatments with paraquat (PQ), LG, or WT for 3 hours. Results were obtained using the image-based cytometry with the Y-axis representative of percent of cells positive for DCF. Values are expressed as a mean ± SD from three independent experiments. Statistical calculations were performed using Two-Way ANOVA multiple comparison for (C) & One-Way ANOVA multiple comparison for (D). ***p < 0.001 vs. Control, ****p < 0.0001 vs. Control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.22502), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56709_mouse-monoclonal-caspase-3-antibody-31a893-310202415535124.jpg)
![Immunohistochemistry-Paraffin: iNOS Antibody (K13-A) [NBP1-33780] - Liver tissue stained with anti-iNOS antibody shows strong positive immunostaining of hepatocytes. Formalin fixed, paraffin embedded human tissues (4 um sections) stained according to IHC-P Protocol for NBP1-33780.](http://images.novusbio.com/fullsize/iNOS-Antibody-K13-A-Immunohistochemistry-Paraffin-NBP1-33780-img0011.jpg "Immunohistochemistry-Paraffin: iNOS Antibody (K13-A) [NBP1-33780] - Liver tissue stained with anti-iNOS antibody shows strong positive immunostaining of hepatocytes. Formalin fixed, paraffin embedded human tissues (4 um sections) stained according to IHC-P Protocol for NBP1-33780.")
![Immunohistochemistry-Paraffin: iNOS Antibody (K13-A) [NBP1-33780] - Lung adenocarcinoma tissue stained with anti-iNOS antibody shows strong positive immunostaining of hepatocytes. Formalin fixed, paraffin embedded human tissues (4 um sections) stained according to IHC-P Protocol for NBP1-33780.](http://images.novusbio.com/fullsize/iNOS-Antibody-K13-A-Immunohistochemistry-Paraffin-NBP1-33780-img0012.jpg)
![Immunohistochemistry-Paraffin: iNOS Antibody (K13-A) [NBP1-33780] - Inflamed porcine intestine. Antibody dilution 1:200, overnight 4C. Secondary anti-rabbit Alexa 488 (1:1000) 2 hr incubation. Image from verified customer review.](http://images.novusbio.com/fullsize/iNOS-Antibody-K13-A-Immunohistochemistry-Paraffin-NBP1-33780-img0010.jpg)
![Western Blot: iNOS Antibody (K13-A) [NBP1-33780] - Effects of omega-3 supplementation on the immunocontent of macrophages M1 markers: nitric oxide synthase 2 (NOS-2) (A) & CD86 (B), & M2 marker: Arginase-1 (C) on the mouse paw muscle 48 h after the model induction in Saline/Sham, Saline/CPIP, Omega-3/CPIP, & Corn oil/CPIP groups. Data are expressed as mean ± SD of 6 animals per group, statistically assessed by the one-way ANOVA followed by Tukey’s test. ##p < 0.01 vs. the Saline/Sham group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35391753), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-33780_rabbit-monoclonal-inos-antibody-k13-a-31020241535639.jpg)
![Western Blot: L1CAM Antibody (UJ127.11) [NB100-2682] - SUM159 cells were exposed to 20% or 1% O2 for 48 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. L1CAM Antibody (NB100-2682) primary antibody: 1:1000, 4C, overnight. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Western-Blot-NB100-2682-img0006.jpg "Western Blot: L1CAM Antibody (UJ127.11) [NB100-2682] - SUM159 cells were exposed to 20% or 1% O2 for 48 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. L1CAM Antibody (NB100-2682) primary antibody: 1:1000, 4C, overnight. Western blot image submitted by a verified customer review.")
![Immunocytochemistry/Immunofluorescence: L1CAM Antibody (UJ127.11) [NB100-2682] - The left panel (A) shows untreated Neuro2a cells and the right panel (B) shows Neuro2a cells that were serum starved then treated with 1mM cAMP overnight to induce axon growth. Cells were fixed in 4% paraformaldehyde for 10 minutes and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti- NB100-2682 at 5 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunocytochemistry-Immunofluorescence-NB100-2682-img0005.jpg)
![Immunohistochemistry-Frozen: L1CAM Antibody (UJ127.11) [NB100-2682] - Human pancreatic ductal adenocarcinoma (PDAC) tissue section stained with L1CAM antibody. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunohistochemistry-Frozen-NB100-2682-img0007.jpg)
![Flow Cytometry: L1CAM Antibody (UJ127.11) [NB100-2682] - A surface stain was performed on HeLa cells with L1CAM Antibody (UJ127.11) NB100-2682 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Flow-Cytometry-NB100-2682-img0001.jpg)
![Western Blot: L1CAM Antibody (UJ127.11) [NB100-2682] - Total protein from human HeLa, A431 and SHSY-5Y cell lines and human Brain was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-L1CAM (NB100-2682) in blocking buffer and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Western-Blot-NB100-2682-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: L1CAM Antibody (UJ127.11) [NB100-2682] - The left panel (A) shows untreated Neuro2a cells and the right panel (B) shows Neuro2a cells that were serum starved then treated with 1mM cAMP overnight to induce axon growth. Cells were fixed in 4% paraformaldehyde for 10 minutes and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti- NB100-2682 at 5 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunocytochemistry-Immunofluorescence-NB100-2682-img0004.jpg)
![Immunohistochemistry-Paraffin: L1CAM Antibody (UJ127.11) [NB100-2682] - Analysis of a FFPE tissue section of human brain using 1:200 dilution of L1CAM [UJ127.11] antibody. The staining was developed using HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. Cytoplasmic and membrane staining as observed in the cerebral cortex](http://images.novusbio.com/fullsize/L1CAM-Antibody-UJ127-11-Immunohistochemistry-Paraffin-NB100-2682-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Ki67/MKI67 Antibody (1297A) NBP2-54791 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Immunocytochemistry-Immunofluorescence-NBP2-54791-img0007.jpg "Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Ki67/MKI67 Antibody (1297A) NBP2-54791 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![<b>Genetic Strategies Validation. </b>Knockout Validated: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - Ki67/MKI67 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line but is not detected in Ki67/MKI67 knockout (KO) HeLa cell line using Rabbit Anti-Human Ki67/MKI67 Monoclonal Antibody (Catalog # NBP2-54791) at 1 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights(TM) 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to nuclei.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Knockout-Validated-NBP2-54791-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP2-54791 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Immunocytochemistry-Immunofluorescence-NBP2-54791-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with Ki67/MKI67 Antibody [1297A] conjugated to Alexa Fluor 647 (NBP2-54791AF647) at 2 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Immunocytochemistry-Immunofluorescence-NBP2-54791-img0010.jpg)
![Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - Ki-67/MKI67 was detected in immersion fixed paraffin-embedded sections of human liver cancer tissue using Rabbit Anti-Human Ki-67/MKI67 Monoclonal Antibody at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody. Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to nuclei. Staining with VisUCyte HRP Polymer Detection Reagents.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Immunohistochemistry-Paraffin-NBP2-54791-img0002.jpg)
![Flow (Intracellular): Ki67/MKI67 Antibody (1297A) [NBP2-54791] - Ki-67/MKI67 Antibody (1297A) [NBP2-54791] - An intracellular stain was performed on Jurkat Cells with Ki-67/MKI67 (1297A) antibody NBP2-54791 (blue) and a matched isotype control MAB1050 (orange). Cells were fixed with 4% paraformaldehyde, following fixation, cells were permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by rabbit IgG APC-conjugated secondary antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Flow-Intracellular-NBP2-54791-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-Ki67/MKI67 (1297A) at 2.0 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Immunocytochemistry-Immunofluorescence-NBP2-54791-img0003.jpg)
![Flow Cytometry: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - An intracellular stain was performed on HeLa cells with Ki67/MKI67 Antibody [1297A] NBP2-54791APC (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Allophycocyanin.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-1297A-Flow-Cytometry-NBP2-54791-img0005.jpg)
![Immunohistochemistry-Paraffin: Ki67/MKI67 Antibody (1297A) [NBP2-54791] - Ki67/MKI67 immunoreactivity in mouse small intestine. NBP2-54791 was diluted to 0.5ug/mL in Antibody Diluent and was left on sections for 1h at room temperature. Secondary was Horse Anti-Rabbit HRP. Image from verified customer review.](http://images.novusbio.com/fullsize/nbp2-54791_rabbit-monoclonal-ki67-mki67-antibody-1297a-1552023121119.jpg)
![Immunohistochemistry-Paraffin: Rabbit Monoclonal Ki67/MKI67 Antibody (1297A) [NBP2-54791] - Ki67 immunoreactivity in FFPE sections of human tonsil. NBP2-54791 was used at 500ng per mL and was left on tissue sections for 1hr at room temperature. Image from a verified customer review.](http://images.novusbio.com/fullsize/nbp2-54791_rabbit-monoclonal-ki67-mki67-antibody-1297a-immunohistochemistry-paraffin-15202512223..jpg)
![Western Blot: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of p50 in HeLa lysate in the A) absence and B) presence of immunizing peptide using p50 antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Western-Blot-NB100-56583-img0004.jpg "Western Blot: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of p50 in HeLa lysate in the A) absence and B) presence of immunizing peptide using p50 antibody at 5 ug/ml.")
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - IHC-P of rabbit aorta using NB100-56583. Secondary antibody: anti-mouse histofine ( Nisherei Bioscience Inc. ref: 414131F). Development: DAB (Dako ref: K346811-2) and counterstained with Hematoxylin. Submitted via verified customer review](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Immunohistochemistry-Paraffin-NB100-56583-img0009.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on U937 cells with NFkB p105/p50 [2J10D7] Antibody NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0008.jpg)
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - analysis of human breast tumor tissue using an isotype control antibody (top) and p50 antibody (bottom) at 5 ug/ml.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Immunohistochemistry-Paraffin-NB100-56583-img0003.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on Jurkat cells with NFkB p105/p50 Antibody (2J10D7) NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes. Both antibodies were conjugated to Dylight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0005.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on HeLa cells with NFkB p105/p50 Antibody (2J10D7) NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes. Both antibodies were conjugated to Dylight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0006.jpg)
![Flow Cytometry: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - An intracellular stain was performed on U2-OS cells with NFkB p105/p50 [2J10D7] Antibody NB100-56583C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/NFkB-p105-p50-Antibody-2J10D7-Flow-Cytometry-NB100-56583-img0007.jpg)
![Immunohistochemistry-Paraffin: NFkB p105/p50 Antibody (2J10D7) [NB100-56583] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of NFkB p105/p50 (2J10D7) antibody. The staining was developed using HRP labeled anti-mouse secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/antibody/nb100-56583_mouse-monoclonal-nfkb-p105-p50-antibody-2j10d7-imgenex-img-5812a-2210202585646.jpg)
![Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer toTakada et al, 2004 for further details). PTD-p65-P6 suppresses TNF-induced NF-kB activation by 25% at 100 uM and completely at 150 uM, where as the control peptide, PTD or p65-P6 without PTD did not have any effect.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser529--p-Ser536]-Inhibitor-Peptide-Set-Western-Blot-NBP2-29321-img0015.jpg "Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer toTakada et al, 2004 for further details). PTD-p65-P6 suppresses TNF-induced NF-kB activation by 25% at 100 uM and completely at 150 uM, where as the control peptide, PTD or p65-P6 without PTD did not have any effect.")
![Western Blot: RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 (3) for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser529--p-Ser536]-Inhibitor-Peptide-Set-Western-Blot-NBP2-29321-img0013.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser529, p Ser536] Inhibitor Peptide Set [NBP2-29321] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-29321) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser529-p-Ser536-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-29321-img0012.jpg)
![Western Blot: Filamin A Antibody (4E10-1B2) [H00002316-M01] - FLNA monoclonal antibody (M01), clone 4E10-1B2 Analysis of FLNA expression in HL-60.](http://images.novusbio.com/fullsize/Filamin-A-Antibody-4E10-1B2-Western-Blot-H00002316-M01-img0009.jpg "Western Blot: Filamin A Antibody (4E10-1B2) [H00002316-M01] - FLNA monoclonal antibody (M01), clone 4E10-1B2 Analysis of FLNA expression in HL-60.")
![Immunohistochemistry-Paraffin: Filamin A Antibody (4E10-1B2) [H00002316-M01] - Analysis of monoclonal antibody to FLNA on formalin-fixed paraffin-embedded human lymphoma tissue. Antibody concentration 1.5 ug/ml.](http://images.novusbio.com/fullsize/Filamin-A-Antibody-4E10-1B2-Immunohistochemistry-Paraffin-H00002316-M01-img0007.jpg)
![Proximity Ligation Assay: Filamin A Antibody (4E10-1B2) [H00002316-M01] - Analysis of protein-protein interactions between GP1BA and FLNA. HeLa cells were stained with anti-GP1BA rabbit purified polyclonal 1:1200 and anti-FLNA mouse monoclonal antibody 1:50. Each red dot represents the detection of protein-protein interaction complex, and nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/Filamin-A-Antibody-4E10-1B2-Proximity-Ligation-Assay-H00002316-M01-img0005.jpg)
![ELISA: Filamin A Antibody (4E10-1B2) [H00002316-M01] - Filamin A Antibody (4E10-1B2) [H00002316-M01] - Detection limit for recombinant GST tagged FLNA is approximately 0.03ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/Filamin-A-Antibody-4E10-1B2-ELISA-H00002316-M01-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - Immunofluorescence analysis of paraformaldehyde fixed U937 cells immobilized on Shi-fix coverslip, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2833-img0015.jpg "Immunocytochemistry/Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - Immunofluorescence analysis of paraformaldehyde fixed U937 cells immobilized on Shi-fix coverslip, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).")
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NB100-2833] - Staining (6ug/ml) of paraffin embedded Human Lung. Heat induced antigen retrieval with citrate buffer pH 6, HRP-Staining.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NB100-2833-img0016.jpg)
![Flow Cytometry: AIF-1/Iba1 Antibody [NB100-2833] - Flow cytometric analysis of paraformaldehyde fixed K562 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Flow-Cytometry-NB100-2833-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - Pg/gingipain is present intracellularly in astrocytes, microglia and neurons in the hippocampus of experimental mice.Green: astrocytes (top panels), microglia (middle panels), and neurons (bottom panels). Red: Pg/gingipain. Blue: DAPI. Representative of N = 4 (GFAP), 3 (Iba1) and 4 (NeuN) experimental mice. Image collected and cropped by CiteAb from the following publication (//journals.plos.org/plosone/article?id=10.1371/journal.pone.0204941), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2833-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - Immunofluorescence analysis of paraformaldehyde fixed CaCo-2 cells immobilized on Shi-fix coverslip, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2833-img0014.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NB100-2833] - Negative Control showing staining of paraffin embedded Human Lung, with no primary antibody.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NB100-2833-img0017.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - Pg/gingipain is present intracellularly in astrocytes, microglia & neurons in the hippocampus of experimental mice.Green: astrocytes (top panels), microglia (middle panels), & neurons (bottom panels). Red: Pg/gingipain. Blue: DAPI. Representative of N = 4 (GFAP), 3 (Iba1) & 4 (NeuN) experimental mice. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30281647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2833_goat-polyclonal-aif-1-iba1-antibody-3102024153430.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - Proinflammatory cytokines IL6, IL1 beta & TNF alpha are evident in the hippocampus of experimental but not in control mice.Data from IF microscopy & RT-PCR. (A-F) Results from IF microscopy. IL6 expression in control (A) & experimental (B) mice, IL1 beta expression in control (C) & experimental (D) mice & TNF alpha expression in control (E) & experimental (F) mice. N = 3 mice/group. (G-I) Gene expression of cytokines was detected by RT-PCR (G, H, I). In all cases, there is significantly higher gene expression of all three cytokines in experimental compared with control group (G, H, I). Green: Iba1, Red: cytokines, Blue: DAPI. N = 5 mice/group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30281647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2833_goat-polyclonal-aif-1-iba1-antibody-31020241535694.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - Proinflammatory cytokines IL6, IL1 beta & TNF alpha are evident in the hippocampus of experimental but not in control mice.Data from IF microscopy & RT-PCR. (A-F) Results from IF microscopy. IL6 expression in control (A) & experimental (B) mice, IL1 beta expression in control (C) & experimental (D) mice & TNF alpha expression in control (E) & experimental (F) mice. N = 3 mice/group. (G-I) Gene expression of cytokines was detected by RT-PCR (G, H, I). In all cases, there is significantly higher gene expression of all three cytokines in experimental compared with control group (G, H, I). Green: Iba1, Red: cytokines, Blue: DAPI. N = 5 mice/group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30281647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2833_goat-polyclonal-aif-1-iba1-antibody-310202415363735.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-2833] - IL-1 beta synthesis, & microglial activation modulation in PDD005-treated aged mice. (A) Images showing IL-1 beta (green fluorescence), iba-1 (red fluorescence) expression. Yellow = Overlay; Blue = nuclei; SGZ region of mouse brain. 40X magnification, scale bar = 100 μm. (B) Graphs representing the average relative fluorescence of Iba-1 in SGZ. Significant differences determined by using one-way ANOVA with Tukey’s test. *P > Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26536027), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2833_goat-polyclonal-aif-1-iba1-antibody-31020241553740.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (QBEnd/10) [NBP2-32932] - Formalin-fixed, paraffin-embedded human tonsil (10X) stained with CD34 MAb (QBEnd/10)](http://images.novusbio.com/fullsize/CD34-Antibody-QBEnd-10-Immunohistochemistry-Paraffin-NBP2-32932-img0001.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (QBEnd/10) [NBP2-32932] - Formalin-paraffin human tonsil (20X) stained with CD34 MAb (QBEnd/10)](http://images.novusbio.com/fullsize/CD34-Antibody-QBEnd-10-Immunohistochemistry-Paraffin-NBP2-32932-img0002.jpg)
![Western Blot: ZIC1 Antibody [NB600-488] - WB analysis of Zic1 in overexpression lysate.](http://images.novusbio.com/fullsize/ZIC1-Antibody-Western-Blot-NB600-488-img0003.jpg "Western Blot: ZIC1 Antibody [NB600-488] - WB analysis of Zic1 in overexpression lysate.")
![Immunohistochemistry-Paraffin: ZIC1 Antibody [NB600-488] - Altered brain pericyte proliferation in Foxc1 mutants. Triple immunofluorescence for Zic1 (pericyte nuclei; green), BrdU (red) and IB4 (blue) highlight proliferating (Zic1+/BrdU+; arrows) pericytes in the E14.5 cerebral vasculature of WT, Foxc1h/h and Foxc1l/l embryos. Image collected and cropped by CiteAb from the following publication (//bio.biologists.org/cgi/doi/10.1242/bio.20135009), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZIC1-Antibody-Immunohistochemistry-Paraffin-NB600-488-img0005.jpg)
![Western Blot: ZIC1 Antibody [NB600-488] - Western blot analysis of Zic1 in mouse cerebellum extract. Protein extracts were prepared from mouse cerebellum between postnatal day 5 (P5) and P18, as indicated above the lanes.](http://images.novusbio.com/fullsize/ZIC1-Antibody-Western-Blot-NB600-488-img0001.jpg)
![Immunohistochemistry: ZIC1 Antibody [NB600-488] - IHC analysis of Zic1 in mouse kidney using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ZIC1-Antibody-Immunohistochemistry-NB600-488-img0004.jpg)
![Immunohistochemistry-Paraffin: ZIC1 Antibody [NB600-488] - Pericyte conditional Foxc1 mutants have increased pericyte proliferation and density in the cerebral vasculature. Zic1 (green), BrdU (red), and IB4 (blue) triple immunofluorescence of E14.5 PDGFrbeta-cre; Foxc1fl-fl mutant and PDGFrbeta-cre; Foxc1fl-+ cerebral cortex. Arrows indicate Zic1+/BrdU+ pericytes. Image collected and cropped by CiteAb from the following publication (//bio.biologists.org/cgi/doi/10.1242/bio.20135009), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZIC1-Antibody-Immunohistochemistry-Paraffin-NB600-488-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Altered brain pericyte proliferation in Foxc1 mutants.(A–C) PDGFr beta (green) & IB4 (red) immunofluorescence highlight pericyte cell bodies in the cortices of E14.5 WT, Foxc1h/h & Foxc1l/l. (D–F) Triple immunofluorescence for Zic1 (pericyte nuclei; green), BrdU (red) & IB4 (blue) highlight proliferating (Zic1+/BrdU+; arrows) pericytes in the E14.5 cerebral vasculature of WT, Foxc1h/h & Foxc1l/l embryos. (G) Graph depicting quantification of Zic1+ pericyte nuclei/vessel length in all three genotypes at E14.5. (H) Graph depicting quantification of pericyte proliferation (labeling index) at E14.5. Scale bars: 100 µm. Means represent analysis of three independent litters for each mutant genotype (n = 3). Asterisks indicate a statistically significance difference from WT (P<0.05). Error bars depict ±SEM. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-310202416163796.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Altered brain pericyte proliferation in Foxc1 mutants.(A–C) PDGFr beta (green) & IB4 (red) immunofluorescence highlight pericyte cell bodies in the cortices of E14.5 WT, Foxc1h/h & Foxc1l/l. (D–F) Triple immunofluorescence for Zic1 (pericyte nuclei; green), BrdU (red) & IB4 (blue) highlight proliferating (Zic1+/BrdU+; arrows) pericytes in the E14.5 cerebral vasculature of WT, Foxc1h/h & Foxc1l/l embryos. (G) Graph depicting quantification of Zic1+ pericyte nuclei/vessel length in all three genotypes at E14.5. (H) Graph depicting quantification of pericyte proliferation (labeling index) at E14.5. Scale bars: 100 µm. Means represent analysis of three independent litters for each mutant genotype (n = 3). Asterisks indicate a statistically significance difference from WT (P<0.05). Error bars depict ±SEM. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-310202416175243.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Pericyte conditional Foxc1 mutants have increased pericyte proliferation & density in the cerebral vasculature.(A,C) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. (B,D) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. Arrowheads indicate PDGFr beta + pericytes. (E,F) Zic1 (green), BrdU (red), & IB4 (blue) triple immunofluorescence of E14.5 PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ cerebral cortex. Arrows indicate Zic1+/BrdU+ pericytes. (G) Graph depicts quantification of Zic1+ pericyte proliferation (labeling index) in the cerebral vasculature at E14.5. (H,J) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. (I,K) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. Arrowheads indicate PDGFr beta + pericytes. (L) Graph depicts pericyte density (Zic1+ pericyte nuclei/vessel length) in the cerebral vasculature at E14.5 & E18.5 in PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ animals. Asterisks indicate a statistically significance difference from PDGFr beta -cre; Foxc1fl-+ samples (P<0.05). Analysis of pericyte proliferation & density was performed on control & mutant brains from three separate litters at each time point (n = 3). Error bars depict ±SEM. Scale bars in A,C,E,F,H,J: 100 µm. Scale bars in B,D,I,K: 50 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-310202416171429.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Pericyte conditional Foxc1 mutants have increased pericyte proliferation & density in the cerebral vasculature.(A,C) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. (B,D) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. Arrowheads indicate PDGFr beta + pericytes. (E,F) Zic1 (green), BrdU (red), & IB4 (blue) triple immunofluorescence of E14.5 PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ cerebral cortex. Arrows indicate Zic1+/BrdU+ pericytes. (G) Graph depicts quantification of Zic1+ pericyte proliferation (labeling index) in the cerebral vasculature at E14.5. (H,J) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. (I,K) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. Arrowheads indicate PDGFr beta + pericytes. (L) Graph depicts pericyte density (Zic1+ pericyte nuclei/vessel length) in the cerebral vasculature at E14.5 & E18.5 in PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ animals. Asterisks indicate a statistically significance difference from PDGFr beta -cre; Foxc1fl-+ samples (P<0.05). Analysis of pericyte proliferation & density was performed on control & mutant brains from three separate litters at each time point (n = 3). Error bars depict ±SEM. Scale bars in A,C,E,F,H,J: 100 µm. Scale bars in B,D,I,K: 50 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-310202416161818.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Pericyte conditional Foxc1 mutants have increased pericyte proliferation & density in the cerebral vasculature.(A,C) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. (B,D) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. Arrowheads indicate PDGFr beta + pericytes. (E,F) Zic1 (green), BrdU (red), & IB4 (blue) triple immunofluorescence of E14.5 PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ cerebral cortex. Arrows indicate Zic1+/BrdU+ pericytes. (G) Graph depicts quantification of Zic1+ pericyte proliferation (labeling index) in the cerebral vasculature at E14.5. (H,J) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. (I,K) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. Arrowheads indicate PDGFr beta + pericytes. (L) Graph depicts pericyte density (Zic1+ pericyte nuclei/vessel length) in the cerebral vasculature at E14.5 & E18.5 in PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ animals. Asterisks indicate a statistically significance difference from PDGFr beta -cre; Foxc1fl-+ samples (P<0.05). Analysis of pericyte proliferation & density was performed on control & mutant brains from three separate litters at each time point (n = 3). Error bars depict ±SEM. Scale bars in A,C,E,F,H,J: 100 µm. Scale bars in B,D,I,K: 50 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-310202416171415.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Pericyte conditional Foxc1 mutants have increased pericyte proliferation & density in the cerebral vasculature.(A,C) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. (B,D) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. Arrowheads indicate PDGFr beta + pericytes. (E,F) Zic1 (green), BrdU (red), & IB4 (blue) triple immunofluorescence of E14.5 PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ cerebral cortex. Arrows indicate Zic1+/BrdU+ pericytes. (G) Graph depicts quantification of Zic1+ pericyte proliferation (labeling index) in the cerebral vasculature at E14.5. (H,J) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. (I,K) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. Arrowheads indicate PDGFr beta + pericytes. (L) Graph depicts pericyte density (Zic1+ pericyte nuclei/vessel length) in the cerebral vasculature at E14.5 & E18.5 in PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ animals. Asterisks indicate a statistically significance difference from PDGFr beta -cre; Foxc1fl-+ samples (P<0.05). Analysis of pericyte proliferation & density was performed on control & mutant brains from three separate litters at each time point (n = 3). Error bars depict ±SEM. Scale bars in A,C,E,F,H,J: 100 µm. Scale bars in B,D,I,K: 50 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-31020241616049.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Pericyte conditional Foxc1 mutants have increased pericyte proliferation & density in the cerebral vasculature.(A,C) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. (B,D) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. Arrowheads indicate PDGFr beta + pericytes. (E,F) Zic1 (green), BrdU (red), & IB4 (blue) triple immunofluorescence of E14.5 PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ cerebral cortex. Arrows indicate Zic1+/BrdU+ pericytes. (G) Graph depicts quantification of Zic1+ pericyte proliferation (labeling index) in the cerebral vasculature at E14.5. (H,J) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. (I,K) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. Arrowheads indicate PDGFr beta + pericytes. (L) Graph depicts pericyte density (Zic1+ pericyte nuclei/vessel length) in the cerebral vasculature at E14.5 & E18.5 in PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ animals. Asterisks indicate a statistically significance difference from PDGFr beta -cre; Foxc1fl-+ samples (P<0.05). Analysis of pericyte proliferation & density was performed on control & mutant brains from three separate litters at each time point (n = 3). Error bars depict ±SEM. Scale bars in A,C,E,F,H,J: 100 µm. Scale bars in B,D,I,K: 50 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-310202416154640.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Pericyte conditional Foxc1 mutants have increased pericyte proliferation & density in the cerebral vasculature.(A,C) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. (B,D) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E14.5. Arrowheads indicate PDGFr beta + pericytes. (E,F) Zic1 (green), BrdU (red), & IB4 (blue) triple immunofluorescence of E14.5 PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ cerebral cortex. Arrows indicate Zic1+/BrdU+ pericytes. (G) Graph depicts quantification of Zic1+ pericyte proliferation (labeling index) in the cerebral vasculature at E14.5. (H,J) Zic1 (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. (I,K) PDGFr beta (green) & IB4 (red) co-immunofluorescence in the cortices of PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ brains at E18.5. Arrowheads indicate PDGFr beta + pericytes. (L) Graph depicts pericyte density (Zic1+ pericyte nuclei/vessel length) in the cerebral vasculature at E14.5 & E18.5 in PDGFr beta -cre; Foxc1fl-fl mutant & PDGFr beta -cre; Foxc1fl-+ animals. Asterisks indicate a statistically significance difference from PDGFr beta -cre; Foxc1fl-+ samples (P<0.05). Analysis of pericyte proliferation & density was performed on control & mutant brains from three separate litters at each time point (n = 3). Error bars depict ±SEM. Scale bars in A,C,E,F,H,J: 100 µm. Scale bars in B,D,I,K: 50 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-310202416182612.jpg)
![Immunocytochemistry/ Immunofluorescence: ZIC1 Antibody - BSA Free [NB600-488] - Altered brain pericyte proliferation in Foxc1 mutants.(A–C) PDGFr beta (green) & IB4 (red) immunofluorescence highlight pericyte cell bodies in the cortices of E14.5 WT, Foxc1h/h & Foxc1l/l. (D–F) Triple immunofluorescence for Zic1 (pericyte nuclei; green), BrdU (red) & IB4 (blue) highlight proliferating (Zic1+/BrdU+; arrows) pericytes in the E14.5 cerebral vasculature of WT, Foxc1h/h & Foxc1l/l embryos. (G) Graph depicting quantification of Zic1+ pericyte nuclei/vessel length in all three genotypes at E14.5. (H) Graph depicting quantification of pericyte proliferation (labeling index) at E14.5. Scale bars: 100 µm. Means represent analysis of three independent litters for each mutant genotype (n = 3). Asterisks indicate a statistically significance difference from WT (P<0.05). Error bars depict ±SEM. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/2/7/647/845/Foxc1-is-required-by-pericytes-during-fetal-brain), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-488_rabbit-polyclonal-zic1-antibody-31020241616060.jpg)
![Western Blot: GAPDH Antibody [NB300-324] - Detection of Human and Mouse GAPDH by Western Blot. Theoretical molecular weight: 36 kDa. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-GAPDH antibody NB300-324 used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-324-img0009.jpg "Western Blot: GAPDH Antibody [NB300-324] - Detection of Human and Mouse GAPDH by Western Blot. Theoretical molecular weight: 36 kDa. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-GAPDH antibody NB300-324 used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.")
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-324] - GAPDH antibody was tested in Hela cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunocytochemistry-Immunofluorescence-NB300-324-img0002.jpg)
![Immunohistochemistry: GAPDH Antibody [NB300-324] - Detection of human GAPDH by immunohistochemistry. Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-GAPDH (NB100-79808). Detection: DAB](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-NB300-324-img0010.jpg)
![Western Blot: GAPDH Antibody [NB300-324] - Detection of Human and Mouse GAPDH, theoretical molecular weight 36 kDa. Whole cell lysate from HeLa (5, 15 and 50 mcg) and mouse NIH3T3 (M; 50 mcg). Affinity purified rabbit anti-GAPDH antibody used at 0.04 mcg/ml. Chemiluminescence with an exposure time of 10 seconds.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-324-img0008.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-324] - IHC detection of GAPDH in formalin-fixed paraffin-embedded human lung carcinoma tissue sections with NB300-324 at a dilution of 1:200](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-Paraffin-NB300-324-img0003.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-324] - IHC detection of GAPDH in formalin-fixed paraffin-embedded mouse squamous cell carcinoma tissue sections with NB300-324 at a dilution of 1:200.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-Paraffin-NB300-324-img0004.jpg)
![Simple Western: GAPDH Antibody [NB300-324] - Simple Western lane view shows a specific band for GAPDH in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Note: band observed higher than predicted molecular weight of 36 kDa.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Simple-Western-NB300-324-img0007.jpg)